

Iduronidase

[View the current Iduronidase InDepth page on BioPortfolio.com](http://www.bioportfolio.com/indepth/Iduronidase.html)

(<http://www.bioportfolio.com/indepth/Iduronidase.html>)

Iduronidase is an enzyme involved in the degeneration of glycosaminoglycans such as dermatan sulfate and heparan sulfate. It is found in the lysosomes of cells.



Recent Publications on Iduronidase:

- [Decreased corneal opacity and improved vision in a patient with mucopolysaccharidosis I \(Hurler-Scheie\) treated with enzyme replacement therapy \(Iaronidase, Aldurazyme\).](#)
*BACKGROUND: Laronidase (Aldurazyme) is a recombinant formulation of...*21st August, 2008
Department of Pediatrics, University Children's Hospital, Badajoz, Spain.- *Am J Med Genet A.* 2008 Jul 1;146A(13):1768-70. ([DOI Direct Link](#))
- [Radiographic evaluation of bones and joints in mucopolysaccharidosis I and VII dogs after neonatal gene therapy.](#)
*Mucopolysaccharidosis I (MPS I) and MPS VII are due to deficient activity...*19th August, 2008
Department of Internal Medicine, Washington University School of Medicine,- *Mol Genet Metab.* 2008 Aug 14. ([DOI Direct Link](#))
- [Co-expression of MGMT\(P140K\) and alpha-L-iduronidase in primary hepatocytes from mucopolysaccharidosis type I mice enables efficient selection with metabolic correction.](#)
*BACKGROUND: Systemic in vivo gene therapy has resulted in widespread...*8th August, 2008
Cell and Molecular Therapy Program, and Division of Experimental- *J Gene Med.* 2008 Mar;10(3):249-59. ([DOI Direct Link](#))
- [Immune response hinders therapy for lysosomal storage diseases.](#)
*Enzyme replacement therapy (ERT) for the lysosomal storage disease...*26th July, 2008
Department of Internal Medicine and Department of Biochemistry and- *J Clin Invest.* 2008 Aug;118(8):2686-9. ([DOI Direct Link](#))
- [Immune tolerance improves the efficacy of enzyme replacement therapy in canine mucopolysaccharidosis I.](#)
*Mucopolysaccharidoses (MPSs) are lysosomal storage diseases caused by a...*26th July, 2008
Division of Medical Genetics, Los Angeles Biomedical Research Institute at- *J Clin Invest.* 2008 Aug 1;118(8):2868-2876. ([DOI Direct Link](#))
- [Structural study on mutant alpha-L-iduronidases: insight into mucopolysaccharidosis type I.](#)
*To elucidate the basis of mucopolysaccharidosis type I (MPS I), we...*17th July, 2008
Department of Analytical Biochemistry, Meiji Pharmaceutical University,- *J Hum Genet.* 2008;53(5):467-74. Epub 2008 Mar 14. ([DOI Direct Link](#))
- [Improved retroviral vector design results in sustained expression after adult gene therapy in mucopolysaccharidosis I mice.](#)
*BACKGROUND: Mucopolysaccharidosis I (MPS I) is a lysosomal storage disease...*10th July, 2008

Department of Internal Medicine, Washington University School of Medicine,- J Gene Med. 2008 Jul 9;10(9):972-982. ([DOI Direct Link](#))

- [Mucopolysaccharidoses type I and IVA: Clinical features and consanguinity in Tunisia.](#)
*Mucopolysaccharidoses (MPS) are a group of lysosomal storage disorders...*1st July, 2008
Laboratory of biochemistry, Farhat-Hached Hospital, 4000 Sousse, Tunisia.- Pathol Biol (Paris). 2008 Jun 25. ([DOI Direct Link](#))
- [Laronidase \(Aldurazyme\): enzyme replacement therapy for mucopolysaccharidosis type I.](#)
*BACKGROUND: Laronidase (Aldurazyme) is a recombinant formulation of...*14th June, 2008
New York University School of Medicine, 403 East 34th Street, 2nd Floor,- Expert Opin Biol Ther. 2008 Jul;8(7):1003-9. ([DOI Direct Link](#))
- [Targeting of the CNS in MPS-IH using a nonviral transferrin-alpha-L-iduronidase fusion gene product.](#)
*Mucopolysaccharidosis type I (Hurler syndrome) is caused by a deficiency...*5th June, 2008
University of Minnesota Cancer Center, Minneapolis, Minnesota, USA.- Mol Ther. 2008 Aug;16(8):1459-66. Epub 2008 Jun 3. ([DOI Direct Link](#))
- [\[Hurler syndrome. Early diagnosis and successful enzyme replacement therapy: a new therapeutic approach. Case report\]](#)
*Mucopolysaccharidosis type I (MPS I) is a lysosomal storage disorder due...*22nd May, 2008
Service de pediatrie, hopital de Lisieux, rue Roger-Aini, 14100 Lisieux,- Arch Pediatr. 2008 Jan;15(1):45-9. Epub 2007 Dec 26. ([DOI Direct Link](#))
- [Upregulation of elastase proteins results in aortic dilatation in mucopolysaccharidosis I mice.](#)
*Mucopolysaccharidosis I (MPS I), known as Hurler syndrome in the severe...*16th May, 2008
Department of Internal Medicine, Washington University School of Medicine,- Mol Genet Metab. 2008 Jul;94(3):298-304. Epub 2008 May 13. ([DOI Direct Link](#))
- [The mild form of mucopolysaccharidosis type I \(Scheie syndrome\) is associated with increased ascending aortic stiffness.](#)
*Mucopolysaccharidosis type I (MPS IS) is a rare autosomal recessive...*5th April, 2008
Department of Cardiology, Thoraxcenter, Erasmus Medical Center Rotterdam,- Heart Vessels. 2008 Mar;23(2):108-11. Epub 2008 Apr 4. ([DOI Direct Link](#))
- [An Autophagic Vacuolar Myopathy-Like Disorder Presenting as Non-Immune Hydrops in a Female Fetus.](#)
*A 37 year-old woman presented for routine obstetrical care at 15 weeks...*15th March, 2008
- Pediatr Dev Pathol. 2008 Feb 25:1. ([DOI Direct Link](#))
- [Drugs and their molecular targets: an updated overview.](#)
*About 330 targets bind approved drugs, 270 encoded by the human genome and...*28th February, 2008
Laboratoire de Pharmacologie, UMR-CNRS 7175, Faculte de Pharmacie,- Fundam Clin Pharmacol. 2008 Feb;22(1):1-18. ([DOI Direct Link](#))

Iduronidase Clinical Trials:



- [A Study Evaluating the Safety and Pharmacokinetics of Aldurazyme® \(Laronidase\) in MPS I Patients Less Than 5 Years Old](#)
Confirmed Diagnosis of Mucopolysaccharidosis I; Less Than 5 Years of Age



Iduronidase Patents:

- 7060497- [Adeno-associated viral vector-based methods and compositions for introducing an expression cassette into a cell](#)
- 7135322- [Expression of lysosomal hydrolase in cells expressing pro-N-acetylglucosamine-1-phosphodiester .alpha.-N-acetyl glucosimanidase](#)
- 7138371- [Remodeling and glycoconjugation of peptides](#)
- 7139666- [Method for identifying or characterizing properties of polymeric units](#)
- 7141582- [Method for enhancing mutant enzyme activities in Gaucher disease](#)
- 7157277- [Factor VIII remodeling and glycoconjugation of Factor VIII](#)
- 7169814- [Guanidinium transport reagents and conjugates](#)
- 7173003- [Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF](#)
- 7179617- [Factor IX: remodeling and glycoconjugation of Factor IX](#)
- 7198776- [Metal complex compounds](#)
- 7198909- [Myeloid precursor cell useful for gene therapy and for modulation of immune responses](#)
- 7129335- [Methods for purifying and isolating recombinant chondroitinases](#)
- 7125843- [Glycoconjugates including more than one peptide](#)
- 7125706- [Method for the production and purification of adenoviral vectors](#)
- 7067127- [GlcNAc phosphotransferase of the lysosomal targeting pathway](#)
- 7071172- [Secretion signal vectors](#)
- 7083937- [Methods and products related to the analysis of polysaccharides](#)
- 7090836- [Vector for expressing .alpha.-L-iduronidase and method of treating MPS I by stereotactic injection into the brain of a mammal](#)
- 7101706- [Polynucleotides and polypeptides encoded thereby distantly homologous to heparanase](#)
- 7105334- [Rationally designed polysaccharide lyases derived from chondroitinase B and methods of specifically cleaving therewith](#)
- 7110889- [Method for identifying or characterizing properties of polymeric units](#)
- 7115391- [Production of recombinant AAV using adenovirus comprising AAV rep/cap genes](#)
- 7117100- [Method for the compositional analysis of polymers](#)
- 7122354- [Nucleic acid encoding a chimeric polypeptide](#)
- 7214660- [Erythropoietin: remodeling and glycoconjugation of erythropoietin](#)
- 7220846- [DNA polymorphisms in sterol regulator element binding proteins](#)
- 7351410- [Treatment of Pompe's disease](#)
- 7354576- [Methods of treating diseases caused by deficiencies of recombinant .alpha.-L-iduronidase](#)
- 7361481- [Diagnosis of lysosomal storage disorders using saposins and other markers](#)
- 7368108- [Glycopeptide remodeling using amidases](#)
- 7371366- [GlcNAc phosphotransferase of the lysosomal targeting pathway](#)
- 7378231- [Diagnosis of lysosomal storage disorders using saposins and other markers](#)
- 7388079- [Delivery of pharmaceutical agents via the human insulin receptor](#)
- 7396811- [Subcellular targeting of therapeutic proteins](#)
- 7399604- [Methods and products related to evaluating the quality of a polysaccharide](#)
- 7399613- [Sialic acid nucleotide sugars](#)
- 7341720- [Targeting of glycoprotein therapeutics](#)
- 7307068- [Use of rapamycin to inhibit immune response and induce tolerance to gene therapy vector and encoded transgene products](#)
- 7297511- [Interferon alpha: remodeling and glycoconjugation of interferon alpha](#)

- 7226903- [Interferon beta: remodeling and glycoconjugation of interferon beta](#)
- 7229961- [Compositions and methods for enhancing drug delivery across and into ocular tissues](#)
- 7232670- [Targeting proteins to cells expressing mannose receptors via expression in insect cells](#)
- 7235391- [Formulation of adenovirus for gene therapy](#)
- 7241442- [Method for producing proteins suitable for treating lysosomal storage disorders](#)
- 7244617- [Diminishing viral gene expression by promoter replacement](#)
- 7265084- [Glycopegylation methods and proteins/peptides produced by the methods](#)
- 7265085- [Glycoconjugation methods and proteins/peptides produced by the methods](#)
- 7276475- [Remodeling and glycoconjugation of peptides](#)
- 7291723- [GB virus C and methods of treating viral infections](#)
- 7402308- [Method of delivering genes to the central nervous system of a mammal](#)

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Wessex Barn, Dorchester Road, Frampton, Dorset, DT2 9NB, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2008 - BioPortfolio Limited.

